Inogen (INGN) Q4 2024 earnings summary

Executive summary

• Achieved $335.7 million in full-year 2024 revenue, up 6.4% year-over-year, and $80.1 million in Q4, up 5.5% year-over-year, driven by strong B2B growth and new product launches.

• Gross margin improved to 45.3% in Q4 and 46.1% for the year, reflecting lower raw material costs and operational efficiencies.

• Net loss and adjusted net loss significantly reduced year-over-year, with Q4 GAAP net loss at $9.8 million and full-year GAAP net loss at $35.9 million; adjusted EBITDA and operating loss also improved.

• Entered a strategic collaboration with Yuwell Medical, including a $27.2 million investment for a 9.9% stake and commercial agreements to expand in China and the US.

• Launched the Rove 4 portable oxygen concentrator and received FDA clearance for the Simeox airway clearance device, expanding the innovation pipeline.

Financial highlights

• Q4 2024 revenue: $80.1 million (+5.5% YoY); full-year 2024 revenue: $335.7 million (+6.4% YoY).

• Q4 gross margin: 45.3% (+821 bps YoY); full-year gross margin: 46.1% (+596 bps YoY), driven by lower raw material costs and operational efficiencies.

• Q4 GAAP net loss: $9.8 million (vs. $26.6 million prior year); full-year GAAP net loss: $35.9 million (vs. $102.4 million prior year).

• Q4 adjusted EBITDA: -$3.6 million (vs. -$17.3 million prior year); full-year adjusted EBITDA: -$9.5 million (vs. -$37.8 million prior year).

• Cash and equivalents at year-end: $117.4 million, no debt.

Outlook and guidance

• Q1 2025 revenue expected at $79–$81 million (1–4% YoY growth).

• Full-year 2025 revenue guidance: $352–$355 million (5–6% YoY growth).

• Gross margin expected at 43–45% for 2025, reflecting new product introductions and channel mix.

• Goal to approach adjusted EBITDA break-even in 2025 through top-line growth and expense management.